Anthropometric data of 14 patients with mucopolysaccharidosis I: Retrospective analysis and efficacy of recombinant human α-l-iduronidase (laronidase)

Molecular Genetics and Metabolism

Volumn 99, Issue 1, 2010, Pages 10-17

  Tylki Szymanska, Anna ^a   Rozdzynska, Agnieszka ^a   Jurecka, Agnieszka ^a   Marucha, Jolanta ^a   Czartoryska, Barbara ^b  

^a CHILDREN'S MEMORIAL HEALTH INSTITUTE   (Poland)

^b INSTITUTE OF PSYCHIATRY AND NEUROLOGY   (Poland)

Author keywords

Anthropometric features; Enzyme replacement therapy; Growth patterns; Growth retardation; Hurler syndrome; Hurler Scheie syndrome; Mucopolysaccharidosis type I; Scheie syndrome

Indexed keywords

LARONIDASE;

ANTHROPOMETRY; ARTICLE; BODY HEIGHT; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEAD CIRCUMFERENCE; HUMAN; HURLER SYNDROME; INFANT; MALE; MEDICAL RECORD REVIEW; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; WEIGHT CHANGE;

ADOLESCENT; ANTHROPOMETRY; BODY HEIGHT; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; ENZYME REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IDURONIDASE; INFANT; MALE; MUCOPOLYSACCHARIDOSIS I; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 71649093573     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2009.08.008     Document Type: Article

References (26)

1. Neufeld E.F., and Muenzer J. The mucopolysaccharidoses. In: Scriver C.R., Beaudet A.L., Sly W.S., et al. (Eds). The Metabolic and Molecular Basis of Inherited Disease (2001), McGraw-Hill, New York 3421-3452
2. Clarke L.A., Wraith J.E., Beck M., et al. Long term efficacy and safety of laronidase in the treatment of mucopolysaccharidoses I. Pediatrics 123 (2009) 229-240
3. Roubicek M., Gehler J., and Spranger J. The clinical spectrum of a-l-iduronidase deficiency. Am. J. Med. Genet. 20 (1985) 471-481
4. Hinek A., and Wilson S.E. Impaired elastogenesis in Hurler disease. Dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am. J. Pathol. 156 (2000) 925-938
5. Pastores G.M., and Meere P.A. Musculoskeletal complications associated with lysosomal storage disorders: Gaucher disease and Hurler-Scheie syndrome (mucopolysaccharidosis type I). Curr. Opin. Rheum. 17 (2005) 70-78
6. Simonaro C.M., D'Angelo M., He X., Eliyahu E., Shtraizent N., Haskins M.E., and Schuchman E.H. Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am. J. Pathol. 172 (2008) 112-122
7. Wraith J.E., Clarke L.A., Beck M., Kolodny E.H., Pastores G.M., Muenzer J., Rapoport D.M., Berger K.I., Swiedler S.J., Kakkis E.D., Braakman T., Chadbourne E., Walton-Bowen K., and Cox G.F. Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-l-iduronidase (laronidase). J. Pediatr. 144 (2004) 581-588
8. Pennock C.A. A review and selection of simple laboratory methods used for the study of glycosaminoglycans excretion and the diagnosis of mucopolysaccharidoses. J. Chem. Pathol. 29 (1976) 111-123
9. A. Malinowski, Dziecko poznanskie. Normy i metody kontroli rozwoju fizycznego. Seria antropologia, third ed., Poznan, 1976.
10. J. Cieslik, M. Kaczmarek, M.D. Kaliszewska-Drozdowska, Dziecko Poznanskie' 90. Wzrastanie, dojrzewanie, normy i metody rozwoju. (The Poznan Child'90. Growth, Development, Reference standards), Wydawnictwo Naukowe Bogucki, Poznan, 1994.
11. Pastores G.M., Arn P., Beck M., Clarke J.T., Guffon N., Kaplan P., Muenzer J., Norato D.Y., Shapiro E., Thomas J., Viskochil D., and Wraith J.E. The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with mucopolysaccharidosis type I. Mol. Genet. Metab. 91 (2007) 37-47
12. Terlato N.J., and Cox G.F. Can mucopolysaccharidosis type I disease severity be predicted based on a patient's genotype? A comprehensive review of the literature. Genet. Med. 5 (2003) 286-294
13. Kakkis E.D., Muenzer J., Tiller G.E., Waber L., Belmont J., Passage M., Izykowski B., Philips J., Doroshow R., Walot I., Hoft R., and Neufeld E.F. Enzyme replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 344 (2001) 182-188
14. Sifuentes M., Doroshow R., Hoft R., Mason G., Walot I., Diament M., Okazaki S., Huff K., Cox G.F., Swiedler S.J., and Kakkis E.D. A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 years. Mol. Genet. Metab. 90 (2007) 171-180
15. Wraith J.E., Beck M., Lane R., van der Ploeq A., Shapiro E., Xue Y., Kakkis E.D., and Guffon N. Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-l-iduronidase (laronidase). Pediatrics 120 (2007) e37-e46
16. Arora R.S., Mercer J., Thornley M., Tylee K., and Wraith J.E. Enzyme replacement therapy in 12 patients with MPS I-H/S with homozygous p.Leu490Pro mutation. J. Inherit. Metab. Dis. 30 (2007) 821
17. Thomas J.A., Jacobs S., Kierstein J., and Van Hove J. Outcome after three years of laronidase enzyme treatment therapy in a patient with Hurler syndrome. J. Inherit. Metab. Dis. 29 (2006) 762
18. Tokic V., Barisic I., Huzjak N., Petkovic G., Fumic K., and Paschke E. Enzyme replacement therapy in two patients with an advanced severe (Hurler) phenotype of mucopolysaccharidosis I. Eur. J. Pediatr. 166 (2007) 727-732
19. Cox-Brinkman J., Smeulders M.J., Hollak C.E., and Wijburg F.A. Restricted upper extremity range of motion in mucopolysaccharidosis type I: no response to one year of enzyme replacement therapy. J. Inherit. Metab. Dis. 30 (2007) 47-50
20. Muenzer J., Wraith J.E., and Clarke L.A. Mucopolysaccharidosis I: management and treatment guidelines. Pediatrics 123 (2009) 19-29
21. Vellodi A., Young E.P., Cooper A., Wraith J.E., Winchester B., Meaney C., Ramaswami U., and Will A. Bone marrow transplantation for mucopolysaccharidosis type I: experience of two British centres. Arch. Dis. Child. 76 (1997) 92-99
22. Polgreen L.E., Tolar J., Plog M., Himes J.H., Orchard P.J., Whitley C.B., Miller B.S., and Petryk A. Growth and endocrine function in patients with Hurler syndrome after hematopoietic stem cell transplantation. Bone Marrow Transplant. 41 (2008) 1005-1011
23. Simonaro C.M., D'Angelo M., Haskins M.E., and Schuchman E.H. Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr. Res. 57 (2005) 701-707
24. Norrdin R.W., Moffat K.S., Thrall M.A., and Grasper P.W. Characterization of osteopenia in feline mucopolysaccharidosis VI and evaluation of bone marrow transplantation therapy. Bone 14 (1993) 361-367
25. Abreu S., Hayden J., Berthold P., Shapiro I.M., Decker S., Patterson D., and Haskins M. Growth plate pathology in feline mucopolysaccharidosis VI. Calcif. Tissues Int. 57 (1995) 185-190
26. Burrow T.A., Hopkin R.J., Leslie N.D., Tinkle B.T., and Grabowski G.A. Enzyme reconstitution/replacement therapy for lysosomal storage diseases. Curr. Opin. Pediatr. 19 (2007) 628-635